Helen Boucher, M.D.,FACP, FIDSA

Contributing Editor

• Dean ad interim & Professor of Medicine, Tufts University School of Medicine
• Chief Academic Officer, Tufts Medicine

Areas of Special Interest

• Infections in immunocompromised patients
• S. aureus infections
• Development of new anti-infective agents

Professional Recognition & Appointments

• Chair, National Institutes of Health (NIH) Antibacterial Resistance Leadership Group (ARLG) Innovations Working Group
• Chair, Board of Trustees of The College of the Holy Cross
• Chair, Board of Trustees of the Physicians of Tufts Medical Center
• Elected Treasurer, Infectious Diseases Society of America (IDSA)
• IDSA Society Citation Award (2015)
• Voting Member, Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (2015)

Publication Highlights

Numerous peer-reviewed scientific articles, textbook chapters, reviews and scientific abstracts including:

• Antibiotic Development Incentives that Reflect Societal Value of Antibiotics. Clin Infect Dis - 2020
• Emergency Use Authorication of Remdesivir: The Need for a Transparent Distribution Process. JAMA - 2020
• Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study. Open Forum Infect Dis - 2020
• The Infectious Diseases Society of America's 10 x '20 Initiative (Ten New Systemic Antibacterial Agents FDA-approved by 2020): Is 20 x '20 a Possibility? Clin Infect Dis - 2019
• Partial Oral Therapy for Osteomyelitis and Endocarditis - Is It Time? N Engl J Med - 2019
• Sequential, Multiple-Assignment, Randomized Trials for Comparing Personalize Antibiotic Strategies (SMART-COMPASS). Clin Infect Dis -2019
• Drug-Use and Post-Operative Mortality Following Valve Surgery for Infective Endocarditis: A Systematic Review and Meta-Analysis. Clin Infect Dis - 2019
• A Multicenter, Randomized, Doubleblind Trial Comparing Efficacy and Safety of Imipenem/ Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis - 2019

Education

• College of the Holy Cross (B.A.)
• University of Texas Medical School at Houston (M.D.)
• Deaconess Hospital (Residency, Chief Resident)
• Beth Israel Deaconess Medical Center (Fellowship)

Disclosures

• Nothing to disclose